Astragaloside IV alleviates septic myocardial injury through DUSP1-Prohibitin 2 mediated mitochondrial quality control and ER-autophagy
This study highlights the potential of AS in the treatment of septic cardiomyopathy and provides a reference for developing cardioprotective drugs targeting DUSP1-PHB2 related mitochondria-ER interaction.
Authors
- Mengyuan Wang
- H. Yang
- Chun Li (ORCID: https://orcid.org/0000-0002-2376-4703)
- Xing Chang
- Junyan Wang (ORCID: https://orcid.org/0000-0002-2048-2225)
- Zhijiang Guo (ORCID: https://orcid.org/0009-0003-5653-8440)
- Haowen Zhuang (ORCID: https://orcid.org/0009-0002-2484-4235)
- Xiangyi Pu
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Guangdong Pharmaceutical University (CN)
- Nantong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- Taizhou Fourth People's Hospital (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Guang’anmen Hospital (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1016/j.jare.2024.10.030
- Citations
- 81
- Primary Topic
- Mitochondrial Function and Pathology
- Type
- article
- Field-Weighted Citation Impact
- 18.94
Funders
- National Natural Science Foundation of China